These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3180823)

  • 21. Aluminum and renal osteodystrophy.
    Sherrard DJ
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):5-11. PubMed ID: 3299591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The spectrum of bone disease in end-stage renal failure--an evolving disorder.
    Sherrard DJ; Hercz G; Pei Y; Maloney NA; Greenwood C; Manuel A; Saiphoo C; Fenton SS; Segre GV
    Kidney Int; 1993 Feb; 43(2):436-42. PubMed ID: 8441240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of aluminium and magnesium effects on initiation and promotion of renal osteodystrophy in patients with chronic renal failure].
    Nakamrua M; Sato N; Tsukamoto Y; Marumo F; Iwanami S
    Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):421-8. PubMed ID: 3747253
    [No Abstract]   [Full Text] [Related]  

  • 24. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 26. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal osteodystrophy.
    Bardin T
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):114S-118S. PubMed ID: 9273952
    [No Abstract]   [Full Text] [Related]  

  • 28. Parathyroid hormone measurements in hemodialysis patients as assessments of renal osteodystrophy.
    Aubry WM; Sparks JC; Braunstein GD
    Mt Sinai J Med; 1984 Apr; 51(2):132-7. PubMed ID: 6610110
    [No Abstract]   [Full Text] [Related]  

  • 29. [Review on internal medicine, 1984. Electrolyte disturbance. III-3. Renal osteodystrophy].
    Ogura Y
    Nihon Naika Gakkai Zasshi; 1985 Jun; 74(6):726-30. PubMed ID: 4045286
    [No Abstract]   [Full Text] [Related]  

  • 30. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone histologic response to deferoxamine in aluminum-related bone disease.
    Andress DL; Nebeker HG; Ott SM; Endres DB; Alfrey AC; Slatopolsky EA; Coburn JW; Sherrard DJ
    Kidney Int; 1987 Jun; 31(6):1344-50. PubMed ID: 2441107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aluminum toxicity in children with chronic renal failure.
    Polinsky MS; Gruskin AB
    J Pediatr; 1984 Nov; 105(5):758-61. PubMed ID: 6389807
    [No Abstract]   [Full Text] [Related]  

  • 33. Renal bone disease.
    Cundy TF; Kanis JA
    Br J Hosp Med; 1985 Jan; 33(1):35-40. PubMed ID: 3882177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy.
    Goldsmith RS; Johnson WJ
    Kidney Int; 1973 Aug; 4(2):154-60. PubMed ID: 4744973
    [No Abstract]   [Full Text] [Related]  

  • 35. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 36. Detection of subtle aluminum-related renal osteodystrophy.
    Romanski SA; McCarthy JT; Kluge K; Fitzpatrick LA
    Mayo Clin Proc; 1993 May; 68(5):419-26. PubMed ID: 7683072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
    De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
    Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 39. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathophysiology and treatment of renal osteodystrophy].
    Ionova D
    Vutr Boles; 1985; 24(6):23-9. PubMed ID: 3913143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.